AWM
VIR icon

Avior Wealth Management’s Vir Biotechnology VIR Stock Holding History

Avior Wealth Management’s Portfolio VIR Stock Details VIR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-16
Closed -$162 – 3689
2024
Q1 		$162 Buy
+16
New +$163 ﹤0.01% 2969

Other funds holding VIR

SIAU
SB Investment Advisers (UK) London, United Kingdom $7.66B AUM 20.12% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
GF
Gates Foundation Seattle, Washington $43.5M AUM 14.19% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Avior Wealth Management's VIR Position: Q2 2024 in Review

Avior Wealth Management sold out of Vir Biotechnology (VIR) in Q2 2024, closing a stake of 16 shares — an estimated $162 sold.

Avior Wealth Management first reported a position in VIR in Q1 2024 and held it in 1 quarter. The position peaked at $162 in Q1 2024. 215 funds tracked by Wall St. Rank hold VIR as of Q2 2024.

  • Avior Wealth Management reported no remaining Vir Biotechnology position as of Q2 2024 after selling out during the quarter.
  • Avior Wealth Management sold 16 Vir Biotechnology shares in Q2 2024, an estimated $162.
  • Avior Wealth Management first reported a position in Vir Biotechnology in Q1 2024 and held it in 1 quarter.
  • Avior Wealth Management's Vir Biotechnology position peaked at $162 in Q1 2024.
  • 215 funds tracked by Wall St. Rank held Vir Biotechnology as of Q2 2024.

Based on Avior Wealth Management's 13F filing for Q2 2024, filed 13 Aug 2024.